Jefferies Global Healthcare Conference
Logotype for CRISPR Therapeutics AG

CRISPR Therapeutics (CRSP) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for CRISPR Therapeutics AG

Jefferies Global Healthcare Conference summary

17 Nov, 2026

Portfolio and pipeline

  • Portfolio spans CASGEVY, later-stage CTX310, zugo-cel and CTX611, plus earlier programs including A1AT, CTX340, type 1 diabetes, in vivo CAR T and in vivo HSC editing.

  • CTX310, zugo-cel and CTX611 could enter late-stage trials within about a year; the 2027 outlook includes continued portfolio progression and potential early CTX340 and A1AT data.

CTX310

  • In severe hypertriglyceridemia, CTX310 showed a mean triglyceride reduction close to 65%; 8 of 10 patients were below 500 at day 28, a threshold associated with reducing pancreatitis risk.

  • LDL, ApoB and non-HDL cholesterol also declined, which was presented as a differentiation from APOC3 approaches; responses had deepened over time in early observations.

  • The one-time ANGPTL3 treatment produced durable lipid reductions through one year in earlier data; further data are expected on glucose control and hepatic fat in the coming year.

  • RMAT designations cover severe hypertriglyceridemia and LDL reduction; management aims to advance quickly toward late-stage trials, with an FDA RMAT meeting expected to help shape a potential Phase III design.

  • Severe hypertriglyceridemia is the initial development path; mixed dyslipidemia and homozygous familial hypercholesterolemia, including patients with inadequate PCSK9 response, are also potential trial settings.

Zugo-cel

  • Zugo-cel is an allogeneic CD19 CAR T with CRISPR edits intended to drive potent expansion while cells are cleared; management sees transient persistence as potentially advantageous for autoimmune disease.

  • In the scleroderma cohort, 6 of 7 patients had an early CRISS-25 response; the 2 patients beyond six months had CRISS-50 responses, with responses reported to deepen over time.

  • Three patients had interstitial lung disease at baseline; no continued decline was observed, and some rapidly progressing patients stabilized. Lung-function improvement may take beyond month six; an update could come in 2027.

  • Trials include lupus, myositis and scleroderma, with neuroimmune indications added; management plans to increase the dose after limited expansion in some patients and cited COGS below $10,000 per patient.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from CRISPR Therapeutics